Product Development Payment Sample Clauses
Product Development Payment. With respect to --------------------------- the period commencing on the Effective Date of this Amendment and ending on the last day of the calendar quarter in which the Effective Date of this Amendment falls and with respect to each succeeding calendar quarter during the term of the Amended LSA, Organogenesis shall submit to Novartis, on a quarterly basis and within thirty (30) days after the end of each just-ended quarter (each, a "Product Submission ------------------ Period"), the invoices, receipts and other written ------ documentation reasonably requested by Novartis (and which is in Organogenesis' possession or Organogenesis can obtain without unreasonable effort or expense), including without limitation the schedules referred to in Article 4.10, setting forth in reasonable detail Organogenesis' research and development and clinical trial costs approved unanimously by the JDC pursuant to Article 4.10 and incurred in good faith during such just-ended Product Submission Period. Novartis shall pay to Organogenesis the Product Development Payment in amounts equal to such costs within thirty (30) days after the end of each Product Submission Period.
Product Development Payment. Epirus shall pay Livzon an aggregate of US$4,500,000 as full consideration to carry out the following activities, inclusive of materials (except sufficient lots of innovator’s reference product, [***]) (the “Pre-Clinical Development Expenses”): the innovator analysis, drug substance process development, characterization work, bioassay, formulation development, [***], and one batch of GMP drug substance material suitable for global Clinical Trial, as further set forth in the Product Development Plan. Epirus shall not be obligated to pay for additional Clinical Supply cost beyond what is already included in the US$4,500,000 payment referred to above. The Pre-Clinical Development Expenses shall be paid by Epirus to Livzon in the following milestone payments within ten (10) days after the date of achievement of the relevant milestones as set forth in the table below: Portions of this Exhibit, indicated by the m▇▇▇ “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Execution of this Supplement $1,500,000 [***] $1,000,000 [***] $1,000,000 [***] $1,000,000
Product Development Payment. Novartis shall --------------------------- pay to Organogenesis, in accordance with Article 7.1, an amount equal to *** of the research and development and clinical trial costs incurred in good faith by Organogenesis during the term of this Agreement, based on schedules to be prepared by Organogenesis CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.
(a) dermatologic (cosmetic) surgery; (b) decubitis ulcers; (c) burn therapy; (d) cryopreserved Apligraf; and (e) such other indications as are agreed upon unanimously by the JDC or its successor committee. The JDC or such successor committee shall allocate resources and expenditures among such indications; provided, that any expenditures -------- shall be subject to the unanimous prior consent of the members of the JDC or such successor committee (it being agreed that any such consent by the JDC shall cover the aggregate amount of expenditures covered by such consent and shall not be revoked without the unanimous consent of the JDC). Novartis shall have the right to review and audit all research and development and clinical trials conducted by or on behalf of Organogenesis with respect to such indications for Product.
Product Development Payment. Without limiting the provisions of Section 6 hereof, DePuy shall pay to Osteotech within three Business Days after the Effective Date the Product Development Payment in consideration of Osteotech's efforts to develop the Products described in EXHIBIT A. The Product Development Payment shall not be refundable by Osteotech regardless of whether such Products are successfully developed and/or become subject to this Agreement. The Product Development Payment shall not cover the development of any products other than those Products described in EXHIBIT A ***.